A professional medical geneticists group recommends that certain genetic risk factors be examined in all medical DNA sequence tests.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
By monitoring the path of stem cells in the body, scientists can better explore experimental therapies, and doctors can better tune treatments in patients.
Neuron-level whole-brain activity maps could one day help explain brain function and disfunction.
Patients can turn off an experimental treatment if side effects get too bad.
A light-sensitive polymer could offer a new way to develop artificial retinas.
Early treatment may be key to a drug-free life for a small percentage of patients.
Sorting concussion patients based on internal brain injury could help doctors identify those with more severe cases.
Broadband communication and custom signal-processing chips power a new brain-recording device that may one day help paralyzed people.
Illumina will work with SynapDx's to find a blood-test that could allow treatment to start earlier.
Researchers explain the goals and structure of a new brain-mapping project.